drugset
drugset / Trial / NCT04400188

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

NCT04400188 ↗

Phase 1/2 Completed 25 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer

Timeline

Start
2020-06-11
Primary completion
2022-01-15
Completion
2022-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody — Other
Subject Fluzoparib Small molecule — Oral
Subject Temozolomide Small molecule — Oral

Indications

small cell lung carcinoma